85 Participants Needed

CUE-101 + Keytruda for Head and Neck Squamous Cell Carcinoma

Recruiting at 16 trial locations
DB
KP
CR
SM
Overseen BySteven Margossian, MD, PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, you cannot have had certain treatments like systemic anti-cancer therapy or radiation therapy within a few weeks before starting the study drug. It's best to discuss your specific medications with the study team.

What data supports the effectiveness of the drug combination CUE-101 and Keytruda for head and neck squamous cell carcinoma?

Research shows that Keytruda (also known as pembrolizumab) is effective in treating head and neck squamous cell carcinoma, especially in patients whose tumors have high levels of PD-L1, a protein that can affect the immune response. This suggests that combining Keytruda with other treatments like CUE-101 might enhance its effectiveness.12345

Is the combination of CUE-101 and Keytruda safe for humans?

Pembrolizumab (Keytruda) has been evaluated for safety in patients with head and neck squamous cell carcinoma, showing some serious side effects like pneumonia and respiratory issues, but its overall safety profile was considered acceptable. There is no specific safety data available for CUE-101 in combination with Keytruda, but pembrolizumab alone has been used safely in various trials.26789

What makes the drug CUE-101 + Keytruda unique for head and neck squamous cell carcinoma?

CUE-101 + Keytruda is unique because it combines CUE-101, a novel immunotherapy, with Keytruda (pembrolizumab), an established immune checkpoint inhibitor, to potentially enhance the immune system's ability to target and destroy cancer cells in head and neck squamous cell carcinoma.156810

What is the purpose of this trial?

This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Research Team

ML

Matteo Levisetti, MD

Principal Investigator

Cue Biopharma

Eligibility Criteria

This trial is for adults over 18 with HPV16+ recurrent or metastatic head and neck squamous cell carcinoma who've had prior systemic therapy. They must have measurable disease, be HLA A*0201 genotype positive, and able to consent to study procedures. Exclusions include HIV/AIDS, hepatitis B/C, other cancers within 2 years, recent major surgery or trauma, significant heart disease, active infections requiring IV treatment, mental incapacity to consent.

Inclusion Criteria

Results from medical tests show certain abnormalities or conditions.
You have advanced head and neck cancer that has worsened after receiving at least one type of treatment. You must have already received platinum-based chemotherapy and/or pembrolizumab as a first-line treatment.
You fully understand the study and have agreed to participate. You are also willing to follow the study procedures and provide the necessary research samples.
See 13 more

Exclusion Criteria

Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome
Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction
Second primary invasive malignancy that has not been in remission for >2 years
See 19 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

CUE-101 Monotherapy IV infusion Q3W Dose Escalation and Expansion, and CUE-101 Dose Escalation in Combination with Pembrolizumab

36 months
Every 3 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

36 months

Treatment Details

Interventions

  • CUE-101
  • Keytruda
Trial Overview The trial is testing CUE-101 alone as a second-line treatment or in combination with Pembrolizumab (KEYTRUDA®) as a first-line treatment. It's an open-label phase 1 study focusing on safety and effectiveness against HPV16+ head and neck cancer.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Pembrolizumab and CUE-101Experimental Treatment2 Interventions
Part C\&D: CUE-101 Dose Escalation in Combination with KEYTRUDA® (pembrolizumab) for injection, for IV use 200 mg Q3W (Part C). Expansion of pembrolizumab plus CUE-101 at the combination RP2D (Part D)
Group II: CUE-101 dose escalation and expansionExperimental Treatment1 Intervention
Part A\&B: CUE-101 Monotherapy IV infusion Q3W Dose Escalation (Part A) and Expansion (Part B)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cue Biopharma

Lead Sponsor

Trials
3
Recruited
160+

Merck Sharp & Dohme LLC

Industry Sponsor

Trials
4,096
Recruited
5,232,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Findings from Research

In a study with 882 patients over a median follow-up of 45 months, pembrolizumab and pembrolizumab-chemotherapy showed significant improvements in overall survival compared to cetuximab-chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma, particularly in patients with high PD-L1 expression (CPS ≥ 20).
The analysis also indicated that patients who received pembrolizumab-based therapies had favorable outcomes in subsequent treatments, with improved progression-free survival on next-line therapies, highlighting the long-term efficacy of pembrolizumab in this patient population.
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.Harrington, KJ., Burtness, B., Greil, R., et al.[2023]
In a study involving 882 participants with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), pembrolizumab alone significantly improved overall survival compared to cetuximab with chemotherapy, especially in patients with high PD-L1 expression (CPS of 20 or more).
Pembrolizumab combined with chemotherapy also showed improved overall survival compared to cetuximab with chemotherapy across all populations, indicating that pembrolizumab is an effective first-line treatment option for HNSCC, particularly for those with PD-L1 positivity.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.Burtness, B., Harrington, KJ., Greil, R., et al.[2021]
In a phase III trial, pembrolizumab, a single-agent treatment, showed significant effectiveness in patients with head and neck tumors that had high PD-L1 expression, leading to deep and lasting responses.
This study highlights the potential of pembrolizumab as a first-line therapy for this specific group of cancer patients, suggesting a targeted approach based on PD-L1 levels.
Pembro Ups Survival in PD-L1-positive HNSCC.[2019]

References

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. [2023]
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. [2021]
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. [2023]
Pembro Ups Survival in PD-L1-positive HNSCC. [2019]
Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma. [2023]
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy. [2019]
Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. [2019]
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. [2021]
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security